GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Effect of Semaglutide on the Inflammatory Response and Clinical Course of Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
NCT06475586 on ClinicalTrials.gov

Status
CompletedResults none
Why it is watched
non-weight indication: inflammation, rheumatologic
Who it enrolls
age 18 Years to 70 Years; no BMI minimum stated; conditions: Psoriasis Vulgaris; Diabetes Type 2
Interventions
Semaglutide
Conditions
Psoriasis Vulgaris; Diabetes Type 2
Phase and size
Phase 4 · 30 participants
Dates
Start 2023-05-03
Primary completion 2024-03-01
Sponsor
University of Banja Luka (Other)
Last checked
Sep 13, 2026
01Endpoints

What the trial will measure

  • clinical characteristics of patients with psoriasisup to 12 weeks
  • Determine BMI Body Mass Indexup to 12 weeks
  • Serum values of TNFa, IL-1b, IL-6, IL-17 and IL-23up to12 weeks
  • Correlation between the course and prognosis of the disease after the treatmentup to 12 weeks
  • Change in HgbA1C,up to 12 weeks
  • lipid status, change in Total cholesterol (TC), low-density lipoprotein(LDL), high-density lipoprotein (HDL) and trigliceridesup to 12 weeks
  • fasting insulinup to 12 weeks
  • Change in inflammation marker level: CRP,up to 12 weeks
  • fasting glycemiaup to 12 weeks
  • urateup to 12 weeks
02Eligibility

Who can take part

Inclusion Criteria: * Patients who signed a personal consent to participate in the study, * Patients with a typical clinical picture of moderately-severe to severe plaque psoriasis (PASI SCORE ≥10) and * DMT2 diagnosed at least 6 months before inclusion in the study, * Patients who were not treated with immunosuppressive therapy. Exclusion Criteria: * Other forms of psoriasis, * Other chronic, inflammatory diseases (data obtained by reviewing the medical history), * Drugs that can cause the appearance of psoriasis (lithium, systemic antimalarials, systemic corticosteroids) - for the past 3 months, * Systemic therapy of vulgaris psoriasis 3 months before inclusion in the study, * Patients on therapy with other GLP-1 RAs except semaglutide (liraglutide, dulaglutide, lixisenatide), SGLT-2 inhibitors (empagliflozin and dapagliflozin) and NSAIDs, photo UVB therapy, * Patients who did not personally sign consent to participate in the study.
03Change log

Registry changes

No changes recorded since the trial was added.